BNP Paribas Arbitrage SA Sells 2,599 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

BNP Paribas Arbitrage SA decreased its holdings in SI-BONE, Inc. (NASDAQ:SIBN) by 68.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 1,215 shares of the company’s stock after selling 2,599 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in SI-BONE were worth $38,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Point72 Hong Kong Ltd raised its position in SI-BONE by 21.8% in the 1st quarter. Point72 Hong Kong Ltd now owns 2,154 shares of the company’s stock valued at $69,000 after purchasing an additional 385 shares during the last quarter. Ellsworth Advisors LLC raised its position in SI-BONE by 7.2% in the 2nd quarter. Ellsworth Advisors LLC now owns 14,612 shares of the company’s stock valued at $460,000 after purchasing an additional 982 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in SI-BONE by 11.0% in the 1st quarter. UBS Asset Management Americas Inc. now owns 11,100 shares of the company’s stock valued at $353,000 after purchasing an additional 1,100 shares during the last quarter. Altshuler Shaham Ltd bought a new position in SI-BONE in the 1st quarter valued at $42,000. Finally, Swiss National Bank raised its position in SI-BONE by 2.8% in the 1st quarter. Swiss National Bank now owns 62,900 shares of the company’s stock valued at $2,001,000 after purchasing an additional 1,700 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Shares of SI-BONE stock opened at $22.50 on Thursday. The company has a quick ratio of 15.13, a current ratio of 15.77 and a debt-to-equity ratio of 0.26. SI-BONE, Inc. has a 12 month low of $19.26 and a 12 month high of $37.21. The business has a fifty day simple moving average of $22.71 and a 200 day simple moving average of $28.43. The stock has a market cap of $748.60 million, a PE ratio of -16.07 and a beta of 1.40.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Sunday, August 1st. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). SI-BONE had a negative return on equity of 30.43% and a negative net margin of 52.47%. The company had revenue of $22.19 million for the quarter, compared to analyst estimates of $22.02 million. Analysts expect that SI-BONE, Inc. will post -1.61 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on SIBN shares. Truist dropped their target price on SI-BONE from $43.00 to $37.00 and set a “buy” rating for the company in a research report on Thursday, September 30th. Truist Securities dropped their target price on SI-BONE from $43.00 to $37.00 and set a “buy” rating for the company in a research report on Thursday, September 30th. Morgan Stanley dropped their target price on SI-BONE from $41.00 to $40.00 and set an “overweight” rating for the company in a research report on Tuesday, August 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $37.00 target price (down previously from $42.00) on shares of SI-BONE in a research report on Tuesday, August 3rd. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $38.00.

In other news, insider Anthony J. Recupero sold 3,384 shares of the company’s stock in a transaction dated Monday, August 16th. The stock was sold at an average price of $20.46, for a total transaction of $69,236.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Dunn sold 2,113 shares of the company’s stock in a transaction dated Friday, July 16th. The stock was sold at an average price of $29.10, for a total value of $61,488.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,299 shares of company stock valued at $400,784. Insiders own 7.00% of the company’s stock.

SI-BONE Profile

SI-BONE, Inc engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-BONE, Inc. (NASDAQ:SIBN).

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.